Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma

Mulaomerović, Adaleta; Halilbasic, Amir; Čičkušić, Elmir; Zavašnik–Bergant, Tina; Begić, Lejla; Kos, Janko

doi:10.1016/j.canlet.2006.07.004

Cited by 43 publications

(37 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found higher levels of cystatin C in sera of patients with early-stage breast cancer as well as those with inflammatory breast cancer compared to the levels previously determined in healthy controls, although the increase was not as significant as in sera of patients with Bcell lymphoma, colorectal cancer or lung cancer (19,37). Although this seems contradictory to its cathepsininhibiting role, higher levels of cystatin C in body fluids have been found in cancer patients and have been associated with a poor prognosis in patients with melanoma, B-cell lymphoma, colorectal cancer and lung cancer (23,(37)(38)(39).…”

Section: Table II -Relationship Between Serum Cathepsin and Cystatin mentioning

confidence: 72%

“…Although this seems contradictory to its cathepsininhibiting role, higher levels of cystatin C in body fluids have been found in cancer patients and have been associated with a poor prognosis in patients with melanoma, B-cell lymphoma, colorectal cancer and lung cancer (23,(37)(38)(39). This may partly be explained by the hypothesis that alterations in secretion may result in higher extracellular and lower intracellular levels of cystatin and cause a reverse correlation with patient survival (39).…”

Section: Table II -Relationship Between Serum Cathepsin and Cystatin mentioning

confidence: 99%

See 1 more Smart Citation

Cathepsin B, Cathepsin H, Cathepsin X and Cystatin C in Sera of Patients with Early-Stage and Inflammatory Breast Cancer

et al. 2008

View full text Add to dashboard Cite

Numerous studies have linked cathepsins and their inhibitor cystatin C to tumor invasion and metastasis. We examined whether cathepsin B, cathepsin H, cathepsin X and cystatin C could be detected in sera from women with earlystage or inflammatory breast cancer and whether they correlated with clinicopathological characteristics. Preoperative serum was obtained from 176 patients with early-stage breast cancer (tumor size ≤5 cm, negative lymph nodes) and 31 patients with inflammatory breast cancer. Cathepsin and cystatin C levels were measured by ELISA. The patient and tumor characteristics under study were age at diagnosis, menopausal status, tumor size, tumor grade, and steroid hormone receptor status. Serum cathepsin B levels were significantly lower in patients with poorly differentiated tumors. High cystatin C levels were associated with tumor size, postmenopausal status and patient age. Interestingly, significantly lower levels of cathepsin X and H were found in patients with inflammatory breast cancer, a trend also observed for cathepsin B and cystatin C.

show abstract

Section: Table II -Relationship Between Serum Cathepsin and Cystatin mentioning

confidence: 72%

Section: Table II -Relationship Between Serum Cathepsin and Cystatin mentioning

confidence: 99%

Cathepsin B, Cathepsin H, Cathepsin X and Cystatin C in Sera of Patients with Early-Stage and Inflammatory Breast Cancer

et al. 2008

View full text Add to dashboard Cite

show abstract

“…In our study, no difference in serum CysC concentrations in patients with and without glucocorticoids was found. It has also been observed that serum CysC levels may be increased as a result of nonHodgkin's lymphoma and certain other malignancies [36][37][38]. Cellular proliferation in patients with proliferative hematological disorders has been shown not to increase serum CysC concentrations [39].…”

Section: Discussionmentioning

confidence: 99%

Comparison of glomerular function tests in children with cancer

et al. 2008

View full text Add to dashboard Cite

Evaluation of renal function should be performed as part of the follow-up during and after chemotherapy in pediatric cancer patients. The aim of this study was to compare an isotope clearance method [isotope glomerular filtration rate (iGFR)] with alternative methods to determine GFR in such patients. Isotope GFR [(99m)Tc-labeled diethylene triaminopentoacetic acid (DTPA) or (51)Cr-labeled ethylenediaminetetra-acetate (EDTA)] was measured in 36 children (112 studies) and compared with simultaneously measured creatinine clearance (CrCl), serum creatinine (SCr), and cystatin C (CysC) concentrations, as well as the results of Schwartz, Counahan-Barratt, and Cockroft-Gault formulae, using general linear mixed models. Our results showed a significant association between iGFR and CysC concentrations (p < 0.001). No linear relationship was observed between CrCl and iGFR (p = 0.7). As expected, the results of height-based formulae (Counahan-Barratt and Schwartz) had significantly (p = 0.004) better correlation to iGFR than the results of a formula based on weight (Cockroft-Gault) (p = 0.19). Despite significant linear correlation, intraclass correlation coefficients showed poor agreement. Tests of similarity between iGFR estimates showed differences between average values of GFR. Therefore, determination of iGFR remains the method of choice in estimation of GFR in cancer patients. In our study population, assay of serum CysC was the most reliable alternative method to measure glomerular function.

show abstract

“…Some studies describe an increase in serum CysC in patients with neoplasia compared to healthy individuals, although renal function was either not assessed (248)(249)(250) or an assessment was based on the serum creatinine alone (243,248,(251)(252)(253) in these studies, greatly limiting their relevance, as acknowledged later by some of the authors themselves (254).…”

Section: Cysc and Cancermentioning

confidence: 99%

Cystatin C: current position and future prospects

Séronie-Vivien

Delanaye

Piéroni³

et al. 2008

Clinical Chemistry and Laboratory Medicine

163

145

View full text Add to dashboard Cite

Cystatin C is a low-molecular-weight protein which has been proposed as a marker of renal function that could replace creatinine. Indeed, the concentration of cystatin C is mainly determined by glomerular filtration and is particularly of interest in clinical settings where the relationship between creatinine production and muscle mass impairs the clinical performance of creatinine. Since the last decade, numerous studies have evaluated its potential use in measuring renal function in various populations. More recently, other potential developments for its clinical use have emerged. This review summarises current knowledge about the physiology of cystatin C and about its use as a renal marker, either alone or in equations developed to estimate the glomerular filtration rate. This paper also reviews recent data about the other applications of cystatin C, particularly in cardiology, oncology and clinical pharmacology. Clin Chem Lab Med 2008;46:1664-86.

show abstract

Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma

Cited by 43 publications

References 18 publications

Cathepsin B, Cathepsin H, Cathepsin X and Cystatin C in Sera of Patients with Early-Stage and Inflammatory Breast Cancer

Cathepsin B, Cathepsin H, Cathepsin X and Cystatin C in Sera of Patients with Early-Stage and Inflammatory Breast Cancer

Comparison of glomerular function tests in children with cancer

Cystatin C: current position and future prospects

Contact Info

Product

Resources

About